Omani experience with the use of factor IX Fc fusion protein.
Source
BMJ Case Reports. v. 14, 7, e241154
Author
Al-Zadjaliyah, Shireen I.
English abstract
We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.
Identifier
DOI: 10.1136/bcr-2020-241154
